139264-57-6

Basic information

• Product Name: (S)-4-(4-Hydrazinobenzyl)-2-oxazolidinone Hydrochloride
• Synonyms: (S)-4-(4-Hydrazinobenzyl)-2-oxazolidinone Hydrochloride
• CAS NO: 139264-57-6
• Molecular Formula: C10H14ClN3O2
• Molecular Weight: 243.69006
• Product Categories: Inhibitors, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 139264-57-6.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• Storage Temp.: Hygroscopic, Refrigerator, under inert atmosphere
• Solubility: DMSO (Slightly), Etthanol (Slightly), Methanol (Slightly)
• Stability: Hygroscopic
• CAS DataBase Reference: (S)-4-(4-Hydrazinobenzyl)-2-oxazolidinone Hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-4-(4-Hydrazinobenzyl)-2-oxazolidinone Hydrochloride(139264-57-6)
• EPA Substance Registry System: (S)-4-(4-Hydrazinobenzyl)-2-oxazolidinone Hydrochloride(139264-57-6)

Safety Data

• Hazardous Substances Data: 139264-57-6(Hazardous Substances Data)

Usage

Description

(S)-4-(4-Hydrazinobenzyl)-2-oxazolidinone Hydrochloride is a chemical compound with a specific molecular structure that features a hydrazinobenzyl group attached to a 2-oxazolidinone ring. (S)-4-(4-Hydrazinobenzyl)-2-oxazolidinone Hydrochloride is known for its ability to interact with biological receptors, particularly the Serotonin 5HTID-receptor, making it a potential candidate for various pharmaceutical and medical applications.

Uses

Used in Pharmaceutical Industry:
(S)-4-(4-Hydrazinobenzyl)-2-oxazolidinone Hydrochloride is used as a Serotonin 5HTID-receptor agonist for its ability to bind and activate the Serotonin 5HTID receptor. This interaction can potentially be utilized in the development of treatments for various conditions related to Serotonin imbalances, such as depression, anxiety, and other mood disorders.
Used in Research and Development:
In the field of research and development, (S)-4-(4-Hydrazinobenzyl)-2-oxazolidinone Hydrochloride can be used as a research tool to study the function and role of the Serotonin 5HTID receptor in cellular processes and signaling pathways. This can contribute to a better understanding of the receptor's role in various physiological and pathological conditions, ultimately leading to the development of more targeted and effective therapeutic strategies.
Used in Drug Design and Synthesis:
The unique structure and receptor-binding properties of (S)-4-(4-Hydrazinobenzyl)-2-oxazolidinone Hydrochloride make it a valuable starting point for the design and synthesis of new drugs targeting the Serotonin 5HTID receptor. By modifying its structure, researchers can potentially develop more potent and selective agonists or antagonists with improved pharmacological properties, such as better bioavailability, reduced side effects, and increased efficacy.

Upstream product

• 56613-61-7 (R)-4-nitro-phenylalanine 
• 187975-62-8 (S)-4-(4-hydrazinobenzyl)-1,3-oxazolidin-2-one 
• 152305-23-2 (S)-4-(4-aminobenzyl)-1,3-oxazolidin-2-one 
• 139264-55-4 (S)-4-(4'-nitrobenzyl)-1,3-oxazolidin-2-one 
• 17193-40-7 (S)-4-nitrophenylalanine methyl ester hydrochloride 
• 89288-22-2 (S)-(-)-2-amino-3-(4-nitrophenyl)propan-1-ol 
• 949-99-5 4-nitro-3-phenyl-L-alanine 

Relevant articles and documents

PROCESS FOR PREPARATION OF ZOLMITRIPTAN

The present invention provides a convenient and industrially viable process for preparation of Zolmitriptan (I) having desired purity. The invention specifically relates to a method for isolating (S)-4-(4-hydrazinobenzyl)-1,3-oxazolidin-2-one hydrochloride (IIIa) of desired purity by separating the undesired inorganic side products such as stannous hydroxide by manipulation of pH at different stages and finally treating with N,N-dimethylamino butyraldehyde diethyl acetal in an acidic medium to provide Zolmitriptan (I) conforming to regulatory specifications.

PROCESS FOR PREPARING ZOLMITRIPTAN COMPOUNDS

In particular, zolmitriptan or a pharmaceutically acceptable salt thereof, which includes a) Preparation of the diazonium salt of the aniline hydrochloride (II); followed by reduction and acidification to give hydrazine (III); b) In situ Reaction of the hydrazine hydrochloride (III) with ?-keto-?-valerolactone, to give the hydrazone (IV); c) Fischer indole synthesis of the hydrazone (IV), to give the pyranoindolone of formula (V); d) Transesterification of the pyranoindolone (V) to provide the compound (VI), in which R means a straight or branched C1-C4 alkyl; e) Conversion of the hydroxyl group of the compound (VI) into dimethylamino to give the indolecarboxylate (VII), in which R means a straight or branched C1-C4 alkyl; f) Saponification of the 2-carboalkoxy group of the compound (VII), to provide indolecarboxylic acid (VIII); g) Decarboxylation of the indolecarboxylic acid (VIII), to provide zolmitriptan and, eventually, to provide a pharmaceutically acceptable salt thereof.

Computer-Aided Design and Synthesis of 5-Substituted Tryptamines and Their Pharmacology at the 5-HT1D Receptor: Discovery of Compounds with Potential Anti-Migraine Properties

The design and synthesis of a series of novel 5-substituted tryptamines with pharmacological activity at 5-HT1D and other monoamine receptors is described.Structural modifications of N- and C-linked (prinicipally hydantoin) analogues at the 5-position were synthesized and their pharmacological activities were utilized to deduce significant steric and electrostatic requirements of the 5-HT1D and 5-HT2A receptor subtypes.Conformations of the active molecules were computed which, when overlaid, suggested a pharmacophore hypothesis which was consistent with the affinity and selectivity measured at 5-HT1D and 5-HT2A receptors.This pharmacophore is composed of a protonated amine site, an aromatic site, a hydrophobic pocket, and two hydrogen-bonding sites.A 'selectively site' was also identified which, if occupied, induced selectivity for 5-HT1D over 5-HT2A in this series of molecules.The development and use of the pharmacophore models in compound design is described.In addition, the physicochemical constraints of molecular size and hydrophobicity required for efficient oral absorption are discussed.Utilizing the pharmacophore model in conjuction with the physicochemical constraints of molecular size and log DpH7.4 led to the discovery of 311C90 (6), a new selective 5-HT1D agonist with good oral absorption and potential use in the treatment of migraine.